melanoma of skin	is a	cancer
melanoma of skin	arises from	melanocyte
melanoma of skin	associated with	ultraviolet radiation
melanoma of skin	associated with	BRAF V600E mutation
melanoma of skin	associated with	NRAS mutation
melanoma of skin	associated with	KIT mutation
melanoma of skin	associated with	CDKN2A mutation
melanoma of skin	associated with	TERT promoter mutation
melanoma of skin	associated with	NF1 mutation
melanoma of skin	treated with	surgical excision
melanoma of skin	treated with	sentinel lymph node biopsy
melanoma of skin	treated with	immunotherapy
melanoma of skin	treated with	targeted therapy
melanoma of skin	treated with	pembrolizumab
melanoma of skin	treated with	nivolumab
melanoma of skin	treated with	ipilimumab
melanoma of skin	treated with	dabrafenib
melanoma of skin	treated with	trametinib
BRAF V600E mutation	predicts response to	BRAF inhibitors
NRAS mutation	predicts resistance to	BRAF inhibitors
melanoma of skin	metastasizes to	regional lymph nodes
melanoma of skin	metastasizes to	liver
melanoma of skin	metastasizes to	brain
melanoma of skin	metastasizes to	lungs
melanoma of skin	metastasizes to	bone
melanoma of skin	prognosis influenced by	Breslow depth
melanoma of skin	prognosis influenced by	ulceration
melanoma of skin	prognosis influenced by	mitotic rate
melanoma of skin	prognosis influenced by	nodal status
melanoma of skin	prognosis influenced by	stage
Breslow depth	correlates with	survival
ulceration	correlates with	poor prognosis
mitotic rate	correlates with	prognosis
sentinel lymph node biopsy	provides	nodal staging
AJCC staging system	used for	melanoma
Clark level	used for	melanoma staging
histopathology	confirms	melanoma of skin
dermatopathology	assesses	melanoma of skin
S100 protein	is marker for	melanoma
HMB-45	is marker for	melanoma
melanoma of skin	presents with	pigmented lesion
melanoma of skin	presents with	ulcerated lesion
melanoma of skin	presents with	nodular growth
ultraviolet exposure	increases risk for	melanoma of skin
tanning bed exposure	increases risk for	melanoma of skin
family history	increases risk for	melanoma of skin
fair skin	increases risk for	melanoma of skin
age	associated with	melanoma incidence
sun protection	reduces risk for	melanoma of skin
sunscreen use	reduces risk for	melanoma of skin
surgical margin	determines	local recurrence risk
wide local excision	achieves	tumor clearance
immunotherapy	improves survival in	advanced melanoma
targeted therapy	improves survival in	BRAF-mutant melanoma
BRAF inhibitors	used for	BRAF V600E mutation melanoma
MEK inhibitors	target	MEK signaling
trametinib	is a	MEK inhibitor
dabrafenib	is a	BRAF inhibitor
nivolumab	is a	monoclonal antibody
pembrolizumab	is a	monoclonal antibody
BRAF V600E mutation	predicts response to	vemurafenib
NRAS mutation	predicts response to	binimetinib
ulceration	indicates	poor prognosis
satellite lesion	indicates	in-transit disease
in-transit metastasis	represents	regional spread
melanoma of skin	has subtype	acral lentiginous melanoma
melanoma of skin	has subtype	nodular melanoma
melanoma of skin	has subtype	lentigo maligna melanoma
melanoma of skin	has subtype	desmoplastic melanoma
Breslow depth	determines	staging
dermoscopy	guides	biopsy decision
excisional biopsy	provides	diagnostic tissue
histology	confirms	melanoma
imaging	evaluates	disease extent
PET-CT	detects	metastasis
MRI brain	detects	brain metastasis
CT chest	detects	pulmonary metastasis
LDH	associated with	prognosis
S100 protein	marker for	melanoma
Melan-A	marker for	melanoma
MART-1	marker for	melanoma
PD-L1 expression	associated with	PD-1 inhibitor response
neural invasion	indicates	poor prognosis
desmoplasia	associated with	melanoma subtype
neoadjuvant therapy	used for	melanoma
adjuvant therapy	used for	high-risk melanoma
clinical trial	offers	novel therapies
neurotrophic factors	influence	melanoma progression
complete response	achieved with	immunotherapy
partial response	achieved with	targeted therapy
stable disease	observed with	MEK inhibitors
progression-free survival	improved by	immunotherapy
overall survival	improved by	targeted therapy
surveillance imaging	monitors	disease progression
subtype melanoma	influences	management strategy
wide local excision	requires	clear margins
adjuvant therapy	reduces recurrence risk
screening programs	improve	early detection
metastatic melanoma	treated with	systemic therapy
multidisciplinary team	manages	melanoma
